• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Prostatype Genomics

0.47 SEK

-0.21 %

Less than 1K followers

PROGEN

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Compare
-0.21 %
-33.05 %
-54.81 %
+56.67 %
-18.97 %
-60.34 %
-99.52 %
-99.93 %
-99.87 %

Prostatype Genomics operates in the medical technology sector. The company specializes in the development of medical genetic tests used for the identification, analysis and further follow-up of prostate cancer. In addition to its main business, related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic market. The head office is located in Nacka Strand.

Read more
Market cap
27.82M SEK
Turnover
67.17K SEK
Revenue
594K
EBIT %
-6,555.22 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
30.6
2026

General meeting '26

23.7
2026

Interim report Q2'26

11.2
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release6/1/2026, 8:45 AM

Prostatype Genomics publishes Annual Report for 2025

Prostatype Genomics
Regulatory press release5/25/2026, 6:45 AM

Update from Prostatype Genomics Regarding the Medicare Reimbursement Process for Prostatype® in the United States

Prostatype Genomics
Regulatory press release5/19/2026, 8:00 PM

NOTICE OF ANNUAL GENERAL MEETING IN PROSTATYPE GENOMICS AB (PUBL)

Prostatype Genomics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/19/2026, 7:50 PM

Prostatype Genomics AB announces the Board of Directors’ intention to resolve on a rights issue of units of approximately SEK 47.4 million

Prostatype Genomics
Regulatory press release2/26/2026, 3:45 PM

Prostatype Genomics publishes year-end report for 2025

Prostatype Genomics
Regulatory press release1/12/2026, 7:55 AM

Loan financing of SEK 10 million to Prostatype Genomics AB

Prostatype Genomics
Regulatory press release1/8/2026, 6:30 PM

Prostatype Genomics U.S. Validation study by Veterans Affairs (VA) is published

Prostatype Genomics
Regulatory press release11/25/2025, 1:30 PM

Prostatype Genomics' Newsletter: Update on Medicare application and publication of U.S. study results

Prostatype Genomics
Press release11/19/2025, 7:06 AM

BioStock: Video from Prostatype Genomic's presentation at BioStock Life Science Summit 2025

Prostatype Genomics
Regulatory press release11/11/2025, 2:45 PM

Previous Investments in Research and Development Unlock Hidden Assets in Prostatype Genomics

Prostatype Genomics
Regulatory press release9/24/2025, 8:45 PM

New shares from exercise of warrants of series TO5 registered

Prostatype Genomics
Regulatory press release9/18/2025, 5:00 PM

Prostatype Genomics AB receives SEK 11.5 million in connection with warrants of series TO5

Prostatype Genomics
Regulatory press release9/12/2025, 7:05 AM

The last day of trading in Prostatype Genomics AB’s warrants of series TO5 is on Monday

Prostatype Genomics
Regulatory press release9/3/2025, 6:55 PM

Prostatype Genomics AB enters into pre-subscription and top-down underwriting commitments corresponding to 37.2 percent in ongoing warrant exercise

Prostatype Genomics
Regulatory press release9/3/2025, 6:45 AM

The exercise period for Prostatype Genomics AB’s warrants of series TO5 commences today

Prostatype Genomics
Regulatory press release9/2/2025, 6:45 AM

Prostatype Genomics AB announces fixed exercise price for warrants of series TO5

Prostatype Genomics
Press release8/28/2025, 2:00 PM

Update regarding Prostatype Genomics’ application to Medicare concerning reimbursement for Prostatype® in USA

Prostatype Genomics
Regulatory press release8/26/2025, 6:30 AM

Prostatype Genomics reaches important commercial breakthrough by initiating billing for Prostatype® to insurance companies in the USA

Prostatype Genomics
Regulatory press release8/7/2025, 6:15 PM

Prostatype Genomics AB changes Certified Adviser to Tapper Partners AB

Prostatype Genomics
Regulatory press release7/23/2025, 10:10 AM

Prostatype Genomics publishes its interim report for the first half of 2025

Prostatype Genomics